Summary

The Asia-Pacific region is home to a diverse and dynamic healthcare landscape. With its burgeoning population, economic growth, and increasing healthcare awareness, the demand for vaccines in this region has been steadily rising. The Asia-Pacific vaccine market has experienced substantial growth in recent years. Factors contributing to this growth include rising healthcare expenditures, expanding immunisation programmes, and increased awareness about the importance of vaccines in preventing infectious diseases. Moreover, the COVID-19 pandemic has underscored the critical role of vaccines in public health, further driving interest and investment in the vaccine sector. Several countries in the Asia-Pacific region have demonstrated impressive progress in expanding their immunisation coverage. Governments and healthcare organisations have worked together to ensure the accessibility and affordability of vaccines for their populations, resulting in increased vaccination rates and reduced disease burden. Major vaccine manufacturers and pharmaceutical companies have recognised the potential of the Asia Pacific market and have made significant investments in research and development, manufacturing facilities, and distribution networks. This has led to the introduction of innovative vaccines tailored to regional needs and disease patterns. For instance, vaccines targeting diseases like dengue, Japanese encephalitis, and hepatitis B are of particular significance in this region. Additionally, collaborations between local and international players have fostered technological advancements and the development of new vaccine platforms. These collaborations are aimed at addressing emerging infectious diseases and enhancing the vaccine supply chain. The region is vulnerable to emerging infectious diseases, making it crucial to adapt quickly to new threats and develop effective vaccines. The vaccine market in the Asia Pacific is well-positioned for future expansion and innovation. Infectious illness burden is decreased, and public health is improved as a result. Maximising the advantages of immunisation in this varied and vibrant area requires addressing the issues of fair access, regulatory barriers, logistics, and vaccine hesitancy.

According to the research report, "Asia-Pacific Vaccines Market Outlook, 2028," published by Bonafide Research, the Asia-Pacific Vaccines market is anticipated to grow at a CAGR of more than 9% by 2023–28. The Asia Pacific vaccine market is influenced by a rich tapestry of cultures, traditions, and healthcare systems across the region. Cultural factors play a significant role in shaping vaccination practices, policies, and public perception. In many countries in Asia and the Pacific, a sense of collective responsibility is deeply ingrained, driving high vaccination rates. Communities often prioritise the well-being of the collective over individual preferences, fostering a culture of immunisation as a means to protect society as a whole. Traditional medicine also plays a vital role in the region's healthcare landscape. In some cultures, traditional remedies coexist with modern vaccines, and integrating these practices can be both a challenge and an opportunity for public health initiatives. Governments and healthcare providers often work to bridge the gap between modern medicine and traditional beliefs to ensure comprehensive vaccination coverage. Moreover, cultural diversity within the Asia-Pacific region necessitates tailored communication strategies. Language, social norms, and religious beliefs can impact vaccine acceptance and access. Sensitivity to these cultural nuances is crucial in vaccine campaigns to build trust and address concerns effectively. Historical events, such as vaccine-related controversies or disease outbreaks, have left lasting imprints on the culture surrounding vaccines in various countries. These events shape public perception, influencing vaccine hesitancy or acceptance. As a result, governments and healthcare organisations must engage in continuous education and awareness campaigns to promote the benefits of vaccination while addressing historical and cultural concerns.

China has seen significant growth in its vaccine market over the years; China boasts the most populous nation. This massive population drives a significant demand for vaccines to prevent and control various diseases. The sheer size of the market provides a substantial customer base for both domestic and international vaccine manufacturers. The Chinese government has historically invested heavily in its healthcare infrastructure and vaccine development. The "Healthy China 2030" initiative and various five-year plans have outlined substantial investments in healthcare, including vaccines, to improve public health outcomes. China has a well-established domestic vaccine industry, with several state-owned and private companies producing a wide range of vaccines. This domestic production capability reduces dependence on imported vaccines and contributes to China's dominant position in the market. China has implemented extensive public health initiatives to control and prevent infectious diseases. Programmes such as the Expanded Programme on Immunisation (EPI) ensure that a wide range of vaccines are accessible to a significant portion of the population, further fueling the vaccine market. The Chinese government has established a robust regulatory framework for vaccines. This framework ensures the safety and efficacy of vaccines, instilling confidence in both domestic and international vaccine manufacturers and consumers. Chinese vaccine manufacturers have expanded their global reach through exports. They supply vaccines to many countries, contributing to China's influence in the global vaccine market.

Based on the technology types, segments include conjugate vaccines, inactivated and subunit vaccines, live attenuated vaccines, recombinant vaccines, and toxoid vaccines. In Asia-Pacific, conjugate vaccines are the leading market. Conjugate vaccines are highly effective in preventing diseases caused by bacteria with polysaccharide capsules, such as pneumococcal diseases, Haemophilus influenza type b (Hib), and meningococcal diseases. Many of these diseases are prevalent in the Asia-Pacific region, making conjugate vaccines a critical tool for public health. Conjugate vaccines are particularly suitable for paediatric vaccination, and child immunisation is a priority in many Asian countries. These vaccines are essential in reducing the burden of diseases that disproportionately affect infants and young children, contributing to better child health outcomes. Conjugate vaccines often provide longer-lasting immunity compared to traditional polysaccharide vaccines. This characteristic is especially valuable in regions where access to healthcare services can be challenging, as it reduces the need for frequent booster shots. Many countries in Asia and the Pacific have established government-sponsored immunisation programmes aimed at preventing specific diseases. Conjugate vaccines are often included in these programmes due to their efficacy and suitability for mass vaccination campaigns. Conjugated vaccines can help reduce the incidence of antibiotic-resistant bacterial infections. This is crucial in Asia and the Pacific, where antibiotic resistance is a growing concern.

In terms of the route of administration, it is segmented into intramuscular and subcutaneous administration, oral administration, and others. Intramuscular injections allow vaccines to be delivered directly into the muscle tissue, which is rich in blood vessels. This facilitates the rapid absorption of the vaccine components into the bloodstream, leading to a strong and effective immune response. This is particularly important in areas where the prevalence of certain diseases necessitates a robust immune reaction. IM administration is suitable for a wide range of vaccines, including those for diseases like measles, mumps, rubella, polio, and hepatitis. Since these diseases are endemic in many parts of Asia and the Pacific, IM administration is an effective way to deliver these vaccines. Many vaccines in the paediatric immunisation schedule, such as the DTP (diphtheria, tetanus, and pertussis) and measles-mumps-rubella (MMR) vaccines, are administered via the IM route. Since paediatric vaccination is a priority in the Asia-Pacific region, the IM route is commonly used to ensure children receive essential vaccines.

Based on the end user segment, which includes paediatrics and adults, in Asia Pacific, adults will grow at the highest CAGR rate by the forecast period. The Asia-Pacific region is witnessing a substantial increase in the proportion of elderly individuals. This demographic shift is driven by advancements in healthcare, improved living conditions, and declining birth rates. As the population ages, there is a higher susceptibility to certain vaccine-preventable diseases, such as influenza, pneumonia, and shingles, which require specialised vaccines tailored for adults. The prevalence of non-communicable diseases, such as cardiovascular diseases, diabetes, and certain cancers, is on the rise in Asia and the Pacific. Many of these conditions weaken the immune system, making adults more susceptible to infections. Vaccines targeting conditions like pneumococcal disease, hepatitis B, and HPV play a crucial role in preventing complications in this population. The Asia-Pacific region is characterised by extensive travel and international trade. This increases the risk of the spread of infectious diseases, making adult vaccination crucial for both personal protection and preventing the international spread of diseases.

Type segmented into multivalent vaccines and monovalent vaccines, in the region multivalent vaccines will grow with the highest CAGR rate by forecast periods. Multivalent vaccines combine multiple antigens or vaccines into a single shot, providing protection against multiple diseases in one administration. This is particularly cost-effective in resource-constrained settings, which are prevalent in parts of the Asia-Pacific region. Governments and healthcare organisations find it more efficient to deliver a single vaccine that covers several diseases, reducing logistics and administration costs. Multivalent vaccines simplify immunisation schedules and reduce the number of healthcare visits needed for vaccination. This is especially beneficial for rural and underserved populations in the Asia Pacific, where access to healthcare facilities can be limited. Streamlined vaccination programmes enhance vaccine coverage rates. In many countries across the Asia Pacific, childhood vaccination is a priority, and multivalent vaccines are often designed to protect against common childhood diseases like diphtheria, tetanus, pertussis, and hepatitis B. These vaccines are essential for reducing child mortality and improving overall child health.

In this report, Dieses types are segmented into the following, rotavirus, pneumococcal diseases, cancer, influenza, diphtheria, pertussis, and tetanus (DTP), human papilloma virus (HPV), hepatitis, shingles, meningococcal diseases, varicella (chicken pox), mumps, and others (dengue, typhoid, polio, Japanese encephalitis, rubella, herpes Zoster, Tuberculosis, and yellow fever). In the Asia-Pacific region, cancer will have the second-highest market share in 2022. The Asia-Pacific region is experiencing a rapid increase in cancer cases. Factors such as ageing populations, changing lifestyles, and increased exposure to risk factors like tobacco use and environmental pollutants have contributed to a higher incidence of cancer. As cancer rates rise, the demand for cancer prevention and treatment measures, including vaccines, has also grown. Many governments in the Asia-Pacific region have recognised the importance of cancer prevention and have introduced vaccination programmes targeting cancers caused by infectious agents. For example, vaccination against the hepatitis B virus (HBV) can prevent liver cancer, which is prevalent in parts of Asia and the Pacific. Government-supported initiatives make cancer vaccines more accessible and contribute to their market share. Increasing awareness about the link between infections and cancer, as well as the benefits of vaccination, has led to greater acceptance of cancer vaccines. Public health campaigns and educational efforts have played a role in boosting the adoption of these vaccines. In some Asia-Pacific countries, cancer screening programmes are becoming more widespread. These programmes often include recommendations for vaccination as part of a comprehensive approach to cancer prevention. Changing demographics, including an ageing population, contribute to the rising cancer burden in the region. Older individuals are at a higher risk of developing cancer, and vaccination can play a role in prevention and early intervention.

In terms of distribution channels, they include hospital pharmacy, retail pharmacy, institutional sales, etc. In Asia Pacific, retail pharmacy is a growing market as the distribution channel of the vaccine market. Retail pharmacies are often conveniently located in urban and rural areas, making vaccines more accessible to a wider population. Patients can receive vaccines without the need for a doctor's appointment, reducing barriers to vaccination. Many countries in the Asia-Pacific region have expanded the scope of practice for pharmacists, allowing them to administer vaccines. This has transformed pharmacies into important vaccination centres, increasing their role in vaccine distribution. Retail pharmacies are increasingly offering a variety of vaccines, including routine childhood vaccines, influenza vaccines, and travel vaccines. This diversification of vaccine offerings makes pharmacies a one-stop destination for immunisation needs. Some governments in the Asia-Pacific region collaborate with retail pharmacies to deliver vaccines as part of public health initiatives. These partnerships aim to increase vaccination coverage rates and ensure that a larger portion of the population has access to vaccines. In Asia Pacific, there are many retail pharmacies that provide many types of vaccines on the market, including Guardian, Watsons, Boots, and many more.

Companies covered in this report:

Merck & Co. Inc, GlaxoSmithKline PLC, Bharat Biotech International Limited, CSL, Charles River Laboratories, Daiichi Sankto Company Ltd, Emergent BioSolutions Inc., Sanofi S.A, Serum Institute of India Pvt. Ltd, Sinovac, AstraZeneca plc, Novavax, Pfizer Inc and Takeda Pharmaceutical Company Limited.

Considered in this report:

• Geography: Asia Pacific
• Historic year: 2017
• Base year: 2022
• Estimated year: 2023
• Forecast year: 2028

Aspects covered in this report:

• Asia Pacific Vaccines market Outlook with its value and forecast along with its segments
• Country-wise Transformers market analysis
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

Country Covered in this report:

• China
• Japan
• India
• Australia
• South Korea

By Technology

• Conjugate vaccines
• Inactivated & Subunit vaccines
• Live Attenuated vaccines
• Recombinant vaccines
• Toxoid vaccines
• Viral vector vaccines
• Others

By Route of Administration

• Intramuscular and subcutaneous administration
• Oral administration
• Others

By End-User Type

• Paediatrics
• Adults


By Disease

• Pneumococcal diseases
• Cancer
• Influenza
• Rotavirus
• Diphtheria, Pertussis, and Tetanus (DTP)
• Human Papilloma Virus (HPV)
• Shingles
• Meningococcal diseases
• Hepatitis
• Varicella (Chicken Pox)
• Mumps
• Others

By Type

• Monovalent vaccines
• Multivalent vaccines

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

The approach of the report:

This report consists of a combined approach of primary as well as secondary research. Initially, secondary research was used to get an understanding of the market and list out the companies that are present in the market. The secondary research consists of third-party sources such as press releases, and annual reports of companies, analyzing the government-generated reports and databases. After gathering the data from secondary sources primary research was conducted by making telephonic interviews with the leading players about how the market is functioning and then conducting trade calls with dealers and distributors of the market. Post this we have started doing primary calls to consumers by equally segmenting consumers into regional aspects, tier aspects, age groups, and gender. Once we have primary data with us we started verifying the details obtained from secondary sources.

Intended audience:

This report can be useful to industry consultants, manufacturers, suppliers, associations & organizations related to the Drone industry, government bodies, and other stakeholders to align their market-centric strategies. In addition to marketing & presentations, it will also increase competitive knowledge about the industry.








***Please Note: It will take 48 hours (2 Business days) for delivery of the report upon order confirmation.

ページTOPに戻る

Table of Contents